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Acyl-ghrelin administration increases food intake, body weight, and blood glucose. In 
contrast, mice lacking ghrelin or ghrelin receptors (GHSRs) exhibit life-threatening 
hypoglycemia during starvation-like conditions but do not consistently exhibit overt 
metabolic phenotypes when given ad libitum food access. These results, and findings of 
ghrelin resistance in obese states, imply nutritional state-dependence of ghrelin’s 
metabolic actions. Here, we hypothesized that LEAP2 (liver enriched antimicrobial 
peptide-2), a recently-characterized endogenous GHSR antagonist, blunts ghrelin 
action during obese states and post-prandially. To test this hypothesis, we determined 
changes in plasma LEAP2 and acyl-ghrelin due to fasting, eating, obesity, Roux-en-Y 
gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), oral glucose administration, 
and type 1 diabetes mellitus (T1DM) using humans and/or mice. Our results suggest 
that plasma LEAP2 is regulated by metabolic status:  its levels increase with body mass 
and blood glucose, and decrease with fasting, RYGB, and in post-prandial states 
following VSG. These changes were mostly opposite to those of acyl-ghrelin. 
Furthermore, using electrophysiology, we showed that LEAP2 both hyperpolarizes and 
prevents acyl-ghrelin from activating arcuate NPY neurons. We predict that the plasma 
LEAP2:acyl-ghrelin molar ratio may be a key determinant modulating acyl-ghrelin 







Ghrelin is a mainly stomach-derived hormone that helps the body respond to changes in 
metabolic state by engaging growth hormone secretagogue receptor (GHSR; ghrelin 
receptor)-expressing neuronal circuits that regulate food intake, body weight, and blood 
glucose (1-4). While ghrelin is found in circulation as both acyl-ghrelin and desacyl-
ghrelin, only acyl-ghrelin, which receives its unique post-translational acylation via 
interaction with ghrelin-O-acyltransferase (GOAT), binds GHSRs with high affinity (5, 6). 
Desacyl-ghrelin nonetheless has some biological activity, in some instances opposing 
acyl-ghrelin actions, although its mechanism of action at physiological levels appears 
GHSR-independent (7-9).  
 
Plasma acyl-ghrelin is regulated at least in part by metabolic status. In both humans and 
rodents, plasma acyl-ghrelin increases during short-term fasting and declines during 
obese states (1, 10-15). Plasma acyl-ghrelin also increases in chronic energy-restricted 
states in rodents, although in humans, prolonged fasting results in a decline in plasma 
acyl-ghrelin (13, 15-17). Plasma acyl-ghrelin levels also are dynamically affected by 
feeding status, with levels rising pre-prandially and falling after a meal (15, 18). These 
changes in plasma acyl-ghrelin suggest prominent actions during conditions of energy 
deficiency. 
 
Acyl-ghrelin administration increases food intake, body weight gain, and blood glucose 
(1, 2, 11, 19). Based on the early characterization of those functions, blockade of acyl-
ghrelin action was predicted to limit food intake, body weight gain, adiposity, and 
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hedonic eating behaviors, and also to lower blood glucose (1, 2, 11, 12, 18, 20, 21). 
However, the initial hope for GHSR antagonism as a therapy for obesity and/or type 2 
diabetes mellitus was tempered by results from genetic mouse models lacking ghrelin, 
GHSR, or GOAT, which do not exhibit marked reductions in food intake or blood 
glucose when food availability is plentiful and do not fully resist the development of diet-
induced obesity (DIO) (22-29). Furthermore, exogenous acyl-ghrelin’s orexigenic effects 
are less potent or absent in DIO mice, suggesting resistance to acyl-ghrelin action 
(ghrelin resistance) in obesity (30-34). Even so, there is mounting evidence for the 
involvement of endogenous acyl-ghrelin in maintaining blood glucose during energy-
restricted states, at least in part through stimulation of growth hormone (GH) secretion 
(16, 17, 25, 35, 36), and its contributions to hyperphagia and hyperglycemia in some 
diabetes models (37-40). The inconsistent ability of endogenous ghrelin to effectively 
function during energy-restricted states but not in DIO suggests the possible existence 
of a regulatory molecule that may limit ghrelin action when food and nutrients are 
plentiful, likely as a natural adaptation to constrain continued increases in food intake 
and blood glucose. 
 
Recently, the liver- and small intestine-derived peptide LEAP2 (liver enriched 
antimicrobial peptide-2) was reported to act as an endogenous antagonist of GHSR 
(41). LEAP2 was first isolated in 2003 from human blood (42) and named due to its 
strong homology to other endogenous antimicrobial peptides despite its weak anti-
bacterial and anti-yeast properties (42). LEAP2 mRNA is expressed predominantly in 
liver, followed by kidney, jejunum, duodenum, stomach, and heart in humans (41-43). 
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LEAP2 is synthesized as a 77 amino acid prohormone in humans (76 amino acids in 
mice) (42) that subsequently is processed to its mature form consisting of 40 amino 
acids with 2 disulfide bridges spanning 4 highly conserved cysteine residues (41, 44). 
The mature LEAP2 sequence is identical in mice and humans. In an attempt to identify 
novel secreted peptide metabolic regulators following vertical sleeve gastrectomy (VSG) 
surgery in mice, the Kaplan lab identified LEAP2 mRNA expression as being increased 
in the stomach remnant and decreased in the duodenum following VSG surgery (41). 
They proceeded to test the activity of LEAP2 against 168 G protein-coupled receptors, 
demonstrating potent GHSR antagonist activity (41). In cell expression systems, LEAP2 
dose-dependently prevented acyl-ghrelin-induced increases of cytosolic calcium and β-
arrestin recruitment (41). Corroborating these in vitro findings, LEAP2 administration 
dose-dependently blocked the effects of administered acyl-ghrelin to induce food intake 
and GH secretion in mice (41). Viral-mediated LEAP2 overexpression phenocopied the 
acyl-ghrelin deficiency-associated life-threatening hypoglycemia reported in ghrelin-
knockout, GOAT-knockout, ghrelin cell-ablated, and ghrelin secretion-defective mouse 
models submitted to a week-long 60% energy restriction protocol modeling starvation 
(13, 16, 17, 25, 35). Suppressing endogenous LEAP2 function in mice with neutralizing 
antibodies was shown to boost fasting-induced increases in GH release, presumably by 
enhancing endogenous acyl-ghrelin action (41). Furthermore, plasma LEAP2, 
measured in lean mice using a newly-developed LEAP2 sandwich ELISA assay, fell 
after a 24 h fast, and then rose by 1 h after re-feeding, in a pattern opposite to that of 
plasma total ghrelin (acyl-ghrelin + desacyl-ghrelin)  (41). Plasma LEAP2 was not 




Here, we tested the hypothesis that LEAP2, similar to acyl-ghrelin, represents a 
metabolic hormone that is regulated by body mass, feeding, and blood glucose, and 
that works in concert with acyl-ghrelin to modulate GHSR activity as a response to 
those metabolic changes. We measured plasma LEAP2 in humans spanning several 
body mass index (BMI) categories and in both lean and obese mice, determining the 
influence of obesity and blood glucose. We also measured the changes in plasma 
LEAP2 after food intake and after two types of bariatric surgery in humans, upon diet-
induced weight loss in mice, and in a type 1 diabetes mellitus (T1DM) mouse model. 
Finally, we used patch-clamp electrophysiology in mouse brain sections to test the 
effects of LEAP2 on spontaneous activity of GHSR-expressing hypothalamic arcuate 
nucleus neuropeptide Y (NPY) neurons – a well-studied target of acyl-ghrelin action (1, 
21, 45-48) and the ability of LEAP2 to antagonize ghrelin-stimulated arcuate NPY 





Validation of commercially-available LEAP2 ELISA kit 
The original report characterizing LEAP2 as an endogenous GHSR antagonist used an 
in-house sandwich ELISA assay to measure plasma LEAP2 in mice, demonstrating a 
67% reduction following a 24 h fast, with partial restoration within 1 h of re-feeding (41).  
To extend these findings to different metabolic conditions and to humans, we first 
validated a commercially-available LEAP2 ELISA kit from Phoenix Pharmaceuticals. 
This kit uses a competitive immunoassay in which a biotinylated LEAP2 peptide 
competes with LEAP2 peptide standard or LEAP2 peptide in the sample for binding to a 
polyclonal LEAP2 antibody. As the full-length peptide sequences of mature LEAP2 from 
humans and mice are identical (Supplemental Figure 1A), the same kit was used for 
both human and mouse samples. Increasing concentrations of the peptide standard 
dose-dependently and fully competed off the biotinylated LEAP2 from binding to the 
LEAP2 antibody, indicating that the LEAP2 levels determined for the samples are 
specific to LEAP2 (Supplemental Figure 1B). Furthermore, concentrations of LEAP2 
peptide from an additional source (Peptide International, Louisville, KY, USA; catalog# 
PLP-4405-s) estimated using the kit matched fairly well the expected concentrations as 
determined from adding a known quantity of peptide to a known volume of assay buffer 
(Supplemental Figure 1C). Spiking mouse plasma containing endogenous LEAP2 with 
increasing amounts of LEAP2 peptide sourced from either Peptide International or 
Phoenix Pharmaceuticals caused an upward parallel shift in the concentration curves 
otherwise determined using the same amounts of LEAP2 peptide in assay buffer, 
indicating that the kit recognizes both the added LEAP2 and endogenous LEAP2 
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(Supplemental Figure 1C). Additional validation of the kit included demonstration of a 
similar reduction in plasma LEAP2 concentrations upon fasting in mice, as published by 
the Kaplan group [(41); see below].  
 
Plasma LEAP2 increases in obese mice and falls after weight loss 
A DIO mouse model was used to assess regulation of LEAP2 by body mass. 
Individually-housed 4 week-old male C57BL/6N mice were provided ad libitum access 
to HFD or standard chow for 16 weeks. As compared to standard chow-fed mice, those 
fed HFD gained more body weight (Figure 1A) and developed higher fat mass and 
higher lean mass (Supplemental Figure 2A-B) over the 16 weeks. Plasma LEAP2 was 
higher by 92% in obese mice than in lean mice (Figure 1B). In contrast, plasma acyl-
ghrelin was lower by 44% in obese mice (Figure 1C). We also compared plasma LEAP2 
levels in each mouse to the corresponding plasma acyl-ghrelin level, generating a 
plasma LEAP2:acyl-ghrelin molar ratio. Obesity increased the plasma LEAP2:acyl-
ghrelin molar ratio by 3.3 fold (Figure 1D). Plasma LEAP2 positively correlated with fat 
mass (Figure 1E) and body weight (Supplemental Figure 2C). Plasma acyl-ghrelin 
negatively correlated with fat mass (Figure 1F) and body weight (Supplemental Figure 
2D). LEAP2 mRNA expression in liver and jejunal mucosal cells of obese mice did not 
differ from that in lean mice (Supplemental Figure 2E), suggesting that the higher 
plasma LEAP2 in obese mice is likely not due to transcriptional upregulation.  
 
Next, we tested if the increased plasma LEAP2 and decreased acyl-ghrelin in DIO can 
be reversed by weight loss. A separate cohort of individually-housed 4-5 week-old male 
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C57BL/6N mice were fed HFD for 8 weeks to induce weight gain, and then either 
allowed to remain on HFD for 4 more weeks or switched back to standard chow for 4 
weeks to induce weight loss. After switching to standard chow, the obese mice lost 
significant body weight, which was statistically indistinguishable from the body weight of 
lean mice maintained on chow for 12 weeks (Figure 1G). The body weight loss was 
accompanied by significant loss of fat mass (Supplemental Figure 3A) but not lean 
mass (Supplemental Figure 3B). Plasma LEAP2 was higher in obese mice at 8 weeks 
than in lean mice (Figure 1H). Plasma LEAP2 fell significantly in the weight loss group 
after 4 weeks on chow when compared to obese mice that were continued on HFD, and 
was statistically indistinguishable from the lean mice maintained on chow for the full 12 
weeks (Figure 1H).  
 
Plasma acyl-ghrelin was lower in obese mice at 8 weeks than lean mice, although it did 
not differ among groups when measured at 12 weeks (Figure 1I). We also analyzed the 
coordinate changes in plasma LEAP2 and acyl-ghrelin by calculating the plasma 
LEAP2:acyl-ghrelin molar ratio. At 8 weeks, obese mice exhibited a higher LEAP2:acyl-
ghrelin molar ratio than that of lean mice (Figure 1J). Weight loss caused a fall in the 
LEAP2:acyl-ghrelin molar ratio (Figure 1J). The fall in fat mass of the weight loss group 
was accompanied by a fall in plasma LEAP2, contributing to a positive correlation of 
plasma LEAP2 with fat mass at 12 weeks (Figure 1K). Plasma LEAP2 also was 
positively correlated with body weight at both 8 weeks and 12 weeks (Supplemental 
Figure 3C,E). Plasma acyl-ghrelin showed a trend for a negative correlation (p=0.068) 
with fat mass at 12 weeks (Figure 1L) and a negative correlation with body weight at 
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both 8 weeks and 12 weeks (Supplemental Figure 3D,F). Interestingly, plasma LEAP2 
in obese mice at 12 weeks was higher than the concentrations measured in the same 
mice at 8 weeks, indicating that plasma LEAP2 continues to increase with further 
increases in body weight (Figure 1M).  
 
Overall, these data indicate that in mice, plasma LEAP2 is positively correlated with 
body weight and fat mass, whereas acyl-ghrelin is negatively correlated with those 
parameters, leading to an elevated plasma LEAP2:acyl-ghrelin molar ratio in obesity. 
Furthermore, diet-induced weight loss can reverse obesity-associated increases in 
plasma LEAP2 and the plasma LEAP2:acyl-ghrelin molar ratio.  
 
Plasma LEAP2 falls with fasting in mice 
Next, we assessed the impact of fasting on plasma LEAP2 in mice. We measured 
plasma LEAP2 and acyl-ghrelin in 9-13 week old male C57BL/6N mice that were either 
fed ad libitum or fasted for 24 h. Fasted mice had lower body weights (Figure 2A) and 
blood glucose (Figure 2B). They also had lower plasma LEAP2 (Figure 2C).  Liver 
LEAP2 mRNA was unchanged (Figure 2D). However, as noted previously (11, 13, 49), 
plasma acyl-ghrelin was higher in fasted mice (Figure 2E). These coordinated changes 
in plasma LEAP2 and acyl-ghrelin, which were similar to those reported by the Kaplan 
lab (41), shifted the plasma LEAP2:acyl-ghrelin molar ratio to a much lower level in 
fasted mice (Figure 2F). Thus, these data indicate that in mice, similar to diet-induced 
weight loss, fasting reduces plasma LEAP2 and increases plasma acyl-ghrelin, thus 




Plasma LEAP2 increases in response to oral glucose administration in mice 
Since plasma acyl-ghrelin is negatively regulated by oral glucose and blood glucose 
(11, 14, 50-52), we tested if an acute increase in blood glucose due to glucose gavage 
leads to an increase in plasma LEAP2 and LEAP2:acyl-ghrelin molar ratio. Eight-twelve 
week-old male C57BL/6N mice fasted 24 h received 2 g/kg glucose or the same volume 
of water by gavage and blood samples were collected after 1 h. Two weeks later, the 
mice underwent the same procedure, again receiving water or 2 g/kg glucose in a 
crossover fashion. Oral glucose increased blood glucose (Figure 3A) and plasma 
LEAP2 (Figure 3B) and decreased plasma acyl-ghrelin (Figure 3C). Plasma 
LEAP2:acyl-ghrelin molar ratio increased by 2-fold (Figure 3D). Blood glucose positively 
correlated with plasma LEAP2 (Figure 3E) and negatively correlated with plasma acyl-
ghrelin (Figure 3F).  Overall, these data indicate that in mice, oral glucose 
administration and/or the ensuing rise in blood glucose raise plasma LEAP2 and lower 
plasma acyl-ghrelin, elevating the plasma LEAP2:acyl-ghrelin molar ratio.   
 
 
Plasma LEAP2 is higher in mouse Type 1 diabetes mellitus model  
Next, we modeled T1DM by administering streptozotocin (STZ, 150 mg/kg BW, i.p.) to 
8-10 week-old male C57BL/6N mice. Six days later, body weight was lower 
(Supplemental Figure 4A) and blood glucose was higher (Figure 3G) in STZ-treated 
mice vs. vehicle-treated mice. Plasma LEAP2 (Figure 3H) was higher in diabetic mice. 
So was plasma acyl-ghrelin (Figure 3I), which is in line with several previous studies 
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(14, 38-40, 53, 54). The parallel STZ-induced rises in plasma LEAP2 and acyl-ghrelin 
translated to an unaltered mean plasma LEAP2:acyl-ghrelin molar ratio (Figure 3J). 
Liver LEAP2 mRNA expression was unaltered by STZ treatment (Supplemental Figure 
4B). Thus, hyperglycemia as induced in the STZ T1DM mouse model raises plasma 
LEAP2, but as it does not reciprocally lower plasma acyl-ghrelin, plasma LEAP2:acyl-
ghrelin molar ratio remains unchanged.   
 
Obesity is associated with higher plasma LEAP2 and lower plasma acyl-ghrelin in 
humans 
Next, we assessed plasma LEAP2 and acyl-ghrelin in a cohort of adults of both sexes 
and spanning several BMI categories [Cohort 1; n=90: lean (n=30, BMI 25 kg/m2), 
overweight (n=33, BMI >25 to 30 kg/m2) and obese (n=27, BMI >30 kg/m2, including 
n=9 with BMI >40 kg/m2; see Supplemental Figure 5 and Supplemental Methods for 
more details]. Fasted plasma LEAP2 concentrations (but not acyl-ghrelin) were also 
available from an additional n=15 adults with obesity (BMI >35 kg/m2) to create an 
expanded cohort of n=105 adults [Cohort 1Ex]: lean (n=30, BMI 25 kg/m2), overweight 
(n=33, BMI >25 to 30 kg/m2), obese (including n=21, BMI >30 to 40 kg/m2 and n=21, 
BMI >40 kg/m2). 
 
Fasted plasma LEAP2 was greater, fasted plasma acyl-ghrelin was lower, and fasted 
plasma LEAP2:acyl-ghrelin molar ratio was greater with greater BMI (Figures 4A-4C). 
Fasted plasma LEAP2 positively correlated with several clinical parameters associated 
with adverse metabolic consequences of obesity, including BMI, % body fat, fasting 
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plasma glucose, homeostatic model assessment of insulin resistance (HOMA-IR), 
fasting serum triglycerides, visceral adipose tissue (AT) volume (VAT), 
VAT/subcutaneous AT volume (SCAT) ratio, and intrahepatocellular lipid (IHCL) 
content, but not with SCAT (Figures 4D-4L). Relationships of fasted plasma acyl-ghrelin 
and fasted plasma LEAP2:acyl-ghrelin molar ratio with these parameters were also 
assessed (see Supplemental Figures 6 and 7, where these correlations appear 
alongside the just-discussed correlations with fasted plasma LEAP2, for comparison). 
As a result of lower plasma acyl-ghrelin in humans with obesity, fasted plasma 
LEAP2:acyl-ghrelin molar ratio had even stronger positive correlations with BMI, % body 
fat, and HOMA-IR than did plasma LEAP2 alone (Supplemental Figure 6). Plasma 
LEAP2:acyl-ghrelin molar ratio was positively correlated with plasma glucose (p=0.086) 
but not with serum triglycerides (Supplemental Figure 6). Unlike LEAP2, there were no 
significant correlations between fasted plasma acyl-ghrelin or fasted plasma 
LEAP2:acyl-ghrelin molar ratio with VAT, SCAT, VAT/SCAT ratio, or IHCL 
(Supplemental Figure 7). Furthermore, there were no significant correlations of fasted 
plasma LEAP2, acyl-ghrelin, or LEAP2:acyl-ghrelin molar ratio with tibialis anterior or 
soleus intramyocellular lipid content (data not shown).  
 
Overall, these data indicate that similar to mice, obesity in humans is associated with 
higher plasma LEAP2, lower plasma acyl-ghrelin, and, in turn, a higher plasma 
LEAP2:acyl-ghrelin molar ratio. Furthermore, plasma LEAP2 is positively correlated with 
several adverse metabolic parameters associated with obesity, including BMI, % body 
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fat, HOMA-IR, fasting plasma glucose and serum triglycerides, VAT volume, and IHCL 
content.  
 
Food intake increases plasma LEAP2 in humans with obesity  
Next, we independently measured plasma LEAP2 and acyl-ghrelin in samples collected 
from a cohort of women with obesity (n=20, BMI >35 kg/m2) and age-matched normal 
weight women (control; n=12, BMI <25 kg/m2) to highlight the impact of food intake on 
plasma LEAP2 and acyl-ghrelin [Cohort 2, see Supplemental Figure 8 and 
Supplemental Methods for more details]. These women were in a study designed 
primarily to assess impact of obesity on brain activation in response to food images; the 
imaging part of that study is published (55). Plasma LEAP2 and acyl-ghrelin were 
measured in these women after an overnight fast (0 h) and again post-prandially (1.5 h 
after the start of a standard 337 kcal meal, which was consumed during a 1 h allocated 
meal time). 
 
Similar to Cohort 1, the Cohort 2 women with obesity had higher plasma LEAP2 as 
compared to normal weight women (Figure 5A). Indeed, fasted plasma LEAP2 
concentrations positively correlated with BMI (Figure 5B). Meal ingestion did not change 
plasma LEAP2 of normal weight women, but did increase plasma LEAP2 in women with 
obesity (p=0.08; Figure 5A). This post-prandial change in plasma LEAP2 (ΔLEAP2 0-
1.5h) positively correlated with BMI (Figure 5C). Also, similar to Cohort 1 [and as 
expected (56-58)], plasma acyl-ghrelin of Cohort 2 women with obesity was lower than 
that of normal weight women (Figure 5D), with plasma acyl-ghrelin concentrations 
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negatively correlating with BMI (Figure 5E). However, plasma acyl-ghrelin did not 
change with food intake in either the normal weight women or women with obesity 
(Figure 5D), in contrast to other clinical studies (18, 49, 56). Finally, just as observed in 
Cohort 1, plasma LEAP2:acyl-ghrelin molar ratio was greater in Cohort 2 women with 
obesity as compared to normal weight women (Figure 5F). However, these plasma 
LEAP2:acyl-ghrelin molar ratios did not change post-prandially in the Cohort 2 groups 
(Figure 5F).  
 
We also examined the effect of food intake in a separate cohort of adults with obesity 
from a bariatric surgery clinic, including many considering Roux-en-Y gastric bypass 
(RYGB) surgery [Cohort 3, see Supplemental Figure 9 and Supplemental Methods for 
more details; notably, plasma acyl-ghrelin was unavailable for Cohort 3]. After ingestion 
of a 600 kCal liquid meal, plasma LEAP2 was higher by 2 h post-prandially (Figure 5G). 
Similar to the 1.5 h post-prandial correlations in Cohort 2 (Figure 5C), the 2 h post-
prandial change in plasma LEAP2 (ΔLEAP2 0-2h) in Cohort 3 also positively correlated 
with BMI (Figure 5H). Serum insulin and plasma glucose were higher by 1 h post-
prandially (Figure 5I and J). Plasma LEAP2 measured at baseline (0 h) and at 1 h and 2 
h post-prandially did not correlate with serum insulin (Figure 5K), but did positively 
correlate with plasma glucose (Figure 5L).  
 
Thus, plasma LEAP2 increases to a greater degree post-prandially in individuals with 
higher BMI. Also, similar to mice, plasma LEAP2 is positively correlated with blood 




RYGB and VSG surgery reduce plasma LEAP2 in humans 
We determined changes in plasma LEAP2 following RYGB in two Cohort 3 subsets, 
and following VSG in a Cohort 2 subset, by comparing the baseline data (Figure 5) to 
post-bariatric surgery data for those participants in whom both data sets were available.  
 
Cohort 3A had overnight-fasted plasma LEAP2 measurements both before and at ~3 
months post-RYGB surgery [n=14 from Cohort 3; see Supplemental Figure 9 and 
Supplemental Methods for more details]; while n=8 of these patients were also studied 
at ~2 years post-RYGB. BMI fell from baseline at both post-RYGB time points, with a 
31.5 ± 3.7% weight loss by 2 years (Figure 6A). Fasted plasma LEAP2 was significantly 
lower at 2 years post-RYGB, but not at 3 months post-RYGB (Figure 6B). Analysis of 
the baseline data together with the 2y-post-RYGB data showed positive correlations 
between fasted plasma LEAP2 with BMI (p=0.096) and plasma glucose (p=0.01) 
(Figures 6C and 6D).  
 
Cohort 3B had baseline (5-6 h after usual breakfast at home) and post-prandial LEAP2 
measurements both before and ~3 months after RYGB surgery, when mean % weight 
loss was 18.3 ± 2.0 [n=11 from Cohort 3; see Supplemental Figure 9 and Supplemental 
Methods for more details]. Plasma LEAP2 increased by 2 h after consumption of the 
600 kCal liquid meal, with no effect of RYGB surgery on the post-prandial increase 
(feeding state x visit interaction p=0.52, effect of feeding state p=0.017) (Figure 6E). 
Furthermore, both baseline and 2 h post prandial plasma LEAP2 significantly decreased 
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after RYGB surgery (overall effect of visit independent of feeding state p=0.055) (Figure 
6E).  
 
Cohort 2A had measurement of plasma LEAP2 and acyl-ghrelin after an overnight fast 
(0 h) and 1.5 h after the start of a standard 337 kcal meal, both before and ~12-18 
months post-VSG surgery [n=7, women with obesity from Cohort 2; see Supplemental 
Figure 8 and Supplemental Methods for more details]. Mean % weight loss was 28.8 ± 
2.7% by ~12-18 months post-VSG surgery (Figure 6F). Post-prandial change in plasma 
LEAP2 by 1.5 h after consumption of the meal varied with VSG surgery (feeding state x 
visit interaction p=0.07), with a statistical trend towards a post-prandial increase in 
LEAP2 observed before VSG surgery (p=0.06), but not at ~12-18 months post-VSG 
surgery (p=0.94) (Figure 6G). Furthermore, the 1.5 h post prandial plasma LEAP2 was 
significantly lower after VSG surgery when compared to before VSG surgery (Figure 
6G). In contrast, both 0 h and 1.5 h post-prandial plasma acyl-ghrelin significantly 
decreased ~12-18 months post-surgery (overall effect of visit independent of feeding 
state p=0.009), with no feeding-dependent change in acyl-ghrelin during either visit 
(Figure 6H). For Cohort 2A, neither VSG nor consuming the standard meal affected 
mean plasma LEAP2:acyl-ghrelin molar ratio, nor was a feeding state x visit interaction 
observed (Figure 6I).  
 
These data indicate that plasma LEAP2 decreases in humans after two different types 
of weight loss surgery. RYGB lowers fasted plasma LEAP2 by 2 years post-surgery, 
and post-prandial plasma LEAP2 by 3 months post-surgery, but does not alter the 
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magnitude of the meal-induced increase in plasma LEAP2. VSG lowers post-prandial 
plasma LEAP2 (as compared to the baseline post-prandial state), and also prevents the 
meal-induced increase in plasma LEAP2. VSG also lowers plasma acyl-ghrelin 
regardless of meal status, leading to no overall change in plasma LEAP2:acyl-ghrelin 
molar ratio by ~12-18 months post-VSG.   
 
LEAP2 acts as a GHSR antagonist and inverse agonist that hyperpolarizes 
arcuate NPY neurons 
To further characterize LEAP2 effects on GHSR action, we performed whole-cell patch-
clamp recordings of arcuate hypothalamic NPY neurons, which highly express GHSRs 
and mediate some of acyl-ghrelin’s orexigenic efficacy (45, 47, 48, 59-61), in brain 
sections prepared from NPY-hrGFP mice (Figure 7A-7D). Similar to previous reports 
(45, 46), application of ghrelin (100 nM) depolarized NPY neurons (change of mean 
membrane potential was 6.7 ± 0.7 mV, Figure 7E, 7H). In contrast, application of LEAP2 
(100 nM) hyperpolarized NPY neurons (change of mean membrane potential was -8.0 ± 
0.6 mV, Figure 7F, 7H). Addition of ghrelin (100 nM) failed to alter NPY neuron 
membrane potential in brain slices pretreated with LEAP2 (100 nM; change of mean 
membrane potential was 0.3 ± 0.2 mV, Figure 7G, 7H). Furthermore, addition of 100 nM 
LEAP2 reversed ghrelin-induced membrane depolarization in all ghrelin-responsive 
NPY neurons examined [change of mean membrane potential with ghrelin application = 
7.5 ± 0.6 mV (Figure 7I, 7J) vs. change in mean membrane potential with addition of 
LEAP2 = -9.3 ±1.1 mV, (Figure 7I,J)]. Notably, 2 of the 6 NPY neurons examined were 
hyperpolarized (by - 5.1mV and -4.0 mV) further from the starting resting membrane 
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potential measured before the addition of ghrelin. Thus, these data suggest that LEAP2 
not only acts as a powerful GHSR antagonist that can incapacitate acyl-ghrelin-induced 
activation of arcuate NPY neurons, but also functions as a GHSR inverse agonist that 
disables GHSR constitutive activity and in so doing, hyperpolarizes NPY neurons and 






In their seminal 2018 paper, Ge et al (41) identified LEAP2 as an endogenous GHSR 
antagonist using in vitro assays. They demonstrated that LEAP2 dose-dependently 
attenuates acyl-ghrelin-induced food intake and GH secretion in mice, that LEAP2 
neutralization boosts fasting-induced GH release in mice, and that LEAP2 
overexpression reproduces the life-threatening hypoglycemia observed in other models 
of deficient acyl-ghrelin action during an energy restriction regimen modeling starvation. 
Furthermore, they demonstrated that fasting is associated with lowering of plasma 
LEAP2 in mice, with partial restoration of plasma LEAP2 by re-feeding, in a pattern 
opposite to that of plasma acyl-ghrelin. Here, we report novel, clinically-relevant findings 
regarding changes in plasma LEAP2 in states of altered energy balance and 
metabolism. These include relationships with obesity and its associated adverse 
metabolic consequences plus effects of food intake and weight loss through energy 
restriction or bariatric surgery, which are complimentary in both mice and humans. We 
have validated the commercially-available LEAP2 ELISA assay kit used in our studies. 
Furthermore, we characterized LEAP2 actions as a GHSR inverse agonist using whole 
cell patch clamp recordings of arcuate NPY neurons within mouse brain sections. 
   
Plasma LEAP2 was higher in obesity, positively correlating with BMI, % body fat, 
plasma glucose, HOMA-IR, serum triglycerides, VAT, VAT/SCAT ratio, and IHCL 
content in humans, and with fat mass and body weight in mice. These findings 
contrasted with those for plasma acyl-ghrelin, which was generally lower in obese 
states. This translated to an increase in the mean plasma LEAP2:acyl-ghrelin molar 
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ratio in obese subjects when compared to control subjects (from 21:1 in lean mice to 
70:1 in obese mice and from 28:1 in normal weight humans to 95:1 in humans with 
obesity). Lower BMI after bariatric surgery (RYGB or VSG) in humans, or after diet-
induced weight loss in mice, was generally associated with lower plasma LEAP2, 
indicating that the rise in plasma LEAP2 linked to the development of obesity can be 
reversed by losing weight. In contrast, plasma LEAP2 was generally lower in fasted 
states than in fed states in mice, contributing to a fall in the mean plasma LEAP2:acyl-
ghrelin molar ratio (from 14:1 in ad libitum-fed mice to 3:1 in fasted mice).  
 
These results suggest that plasma LEAP2 is sensitive to body weight and feeding status 
and is usually (with a few exceptions noted below) regulated in a manner diametrically 
opposite to plasma acyl-ghrelin. We propose a model (Figure 8) in which the rise in 
plasma LEAP2 together with the fall in plasma acyl-ghrelin could be a major contributor 
to the ghrelin resistance observed during obese states (34). In contrast, the coordinated 
fall in plasma LEAP2 together with the rise in plasma acyl-ghrelin is proposed to create 
a permissive environment for acyl-ghrelin to potently act during energy restricted states. 
Thus, we predict that the plasma LEAP2:acyl-ghrelin molar ratio could be a key 
determinant modulating GHSR actions in response to changes in body mass, feeding 
status, and blood glucose.  
 
Ghrelin activates GHSR with an EC50 of 2.5 to 7.1 nM (3, 41), and LEAP2 acts as a 
GHSR antagonist with an IC50 of 6 nM (41). Therefore, the potency of LEAP2 as a 
GHSR antagonist is very close to the potency of ghrelin as a GHSR agonist (41). The 
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mean ad libitum-fed plasma LEAP2 concentration in our mouse studies (on average 
~20 ng/mL or 4.4 nM) using a commercial ELISA kit was similar to the concentration 
measured by Ge et al. (41), who used a custom ELISA kit, and is close to the IC50 for 
GHSR (6 nM) (41). Therefore, we confirm the conclusion by Ge et al (41) that LEAP2, at 
its physiological circulating concentrations, would be very effective as a GHSR 
antagonist. Such a conclusion is supported by the increases in GHSR-mediated GH 
secretion after immunoneutralization of endogenous LEAP2 in mice even during fasted 
conditions, when plasma LEAP2 is lower than during the ad libitum-fed condition [Figure 
2, (41)]. Interestingly, the plasma LEAP2 concentrations we measured in both humans 
and mice are more than 1000-fold lower than the IC50 for its originally-described 
antimicrobial activity (~5 µM), suggesting that the prominent physiological function of 
circulating LEAP2 is as a GHSR antagonist rather than its first characterized function as 
an antimicrobial peptide (42). Here, we also observed that the concentration of plasma 
LEAP2 in the ad libitum-fed state is > 20-fold higher than that of plasma acyl-ghrelin in 
both mice and humans. Therefore, given the roughly equal potency as well as affinity of 
the two peptides for GHSR (41, 62, 63), it is likely that in the fed state, LEAP2 serves as 
the dominant ligand of GHSR, prominently antagonizing acyl-ghrelin actions. In the 
fasted state, the fall in the LEAP2:acyl-ghrelin molar ratio likely favors a relatively higher 
proportion of acyl-ghrelin binding to mediate its effects through GHSR. This potentially 
explains why genetic deletion of endogenous ghrelin does not have pronounced 
metabolic effects in ad libitum-fed conditions but does upon energy restriction (2, 16, 24, 




Our electrophysiology results using mouse brain sections, as well as recent studies 
using heterologous cell expression systems (62, 63), confirm that LEAP2 opposes acyl-
ghrelin actions on GHSR. However, our findings were unlike the original discovery by 
Ge at al., which, based on experiments utilizing a β-arrestin recruitment assay in a cell 
line stably expressing GHSRs, described LEAP2 as a “classic” GHSR antagonist with 
no intrinsic activity (41). Instead, our studies demonstrating hyperpolarization of mouse 
arcuate NPY neurons by application of LEAP2 alone, as opposed to the expected 
observation of no effect on neuronal activity if LEAP2 was a “classic” antagonist, 
indicate that LEAP2 acts as an inverse agonist rather than simply as an antagonist of 
acyl-ghrelin action on GHSRs. This conclusion is further supported by a recent study 
which observed a 50% decrease in inositol phosphate 1 intracellular second messenger 
levels upon LEAP2 treatment of GHSR-expressing HEK293T cells (62).  
 
Acyl-ghrelin stimulates food intake at least in part by engaging GHSRs expressed in 
orexigenic arcuate NPY/AgRP neurons (36, 45, 47, 61, 65, 66). However, in DIO mice, 
the orexigenic response to acyl-ghrelin administration is blunted or absent (30-34, 67).  
Also, acyl-ghrelin fails to stimulate food intake, induce arcuate c-fos immunoreactivity, 
or increase arcuate NPY and AgRP mRNA expression in DIO mice, as occur upon acyl-
ghrelin administration to chow-fed mice, suggesting the development of ghrelin 
resistance in obese states (19, 30-34, 68). Our results demonstrating elevated plasma 
LEAP2 in DIO, and inhibition of spontaneous and acyl-ghrelin-induced increases in 
arcuate NPY neuronal activity suggest that LEAP2 could be an important component of 
the altered endocrine feedback during DIO, directly affecting GHSR function, and in 
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particular, leading to ghrelin resistance. Future loss-of-LEAP2 function genetic mouse 
model studies will help reveal the contribution of LEAP2 to the ghrelin resistance 
associated with DIO.  
 
We also find that plasma LEAP2, similar to plasma acyl-ghrelin, is regulated 
dynamically by feeding status. Plasma LEAP2 was higher in ad libitum-fed lean mice 
than in fasted mice, as had been noted by Ge et al (41), whereas plasma acyl-ghrelin 
was lower (1, 10-15). Oral glucose administration had the same effect in mice to 
increase plasma LEAP2. A post-prandial change in plasma LEAP2 also was observed 
in two separate human cohorts. In both cohorts, LEAP2 positively correlated with BMI, 
and the post-prandial increase was present only in the obese group but not the normal 
weight group. Thus, the higher the BMI, the more plasma LEAP2 will rise after a meal.  
 
Altogether, the results discussed so far suggest that the plasma LEAP2 depends on 
both the long-term, underlying metabolic state (e.g. body mass and adiposity) as well as 
more short-term, meal-dependent changes in nutrient availability. The human studies 
suggest that plasma LEAP2 is highest in individuals with obesity after meals, possibly 
functioning as a nutritional “sufficiency hormone” that provides endocrine feedback to 
key brain regions contributing to the feelings of satiety and satiation. Interestingly, the 
human studies demonstrated higher fasted plasma LEAP2 only in those with BMI >35-
40 kg/m2, suggesting that milder degrees of obesity may not be associated with the 
‘protective’ elevations of LEAP2, and might benefit from therapies that would boost 
plasma LEAP2 (for instance, to curb appetite and reduce food reward). Similarly, 
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therapies that increase plasma LEAP2 might also be beneficial particularly in individuals 
with obesity who have achieved weight loss, so as to counteract the naturally-occurring 
falls in LEAP2 that otherwise may contribute to rebound weight gain, coincident with 
increases in plasma ghrelin (69, 70). Such LEAP2-based therapies could be impactful 
after lifestyle modification or gastric banding surgery, in which there is no coincident 
beneficial increase in satiety gut hormones, such as peptide YY (PYY) and glucagon-
like peptide 1, or decrease in acyl-ghrelin, unlike after RYGB and/or VSG surgery. 
 
The effects of oral glucose administration in mice were similar to those of food intake in 
mice and humans to increase plasma LEAP2 and decrease plasma acyl-ghrelin. These 
effects may therefore be driven by presence of nutrients, and in particular glucose, in 
the gut, or via associated increases in glucose or insulin in the systemic circulation or 
hepatic portal vein (52). Interestingly, insulin directly reduces stomach-derived ghrelin 
secretion (52). Our data suggest that blood glucose may itself regulate plasma LEAP2, 
independently of body mass or feeding status. Indeed, fasted plasma LEAP2 positively 
correlated with blood glucose and insulin resistance in a human cohort across a broad 
range of BMIs, and with post-prandial glucose but not insulin in another human cohort 
with obesity. Furthermore, the higher blood glucose in a T1DM mouse model of insulin 
deficiency was associated with higher plasma LEAP2, suggesting a more important role 
for increases in blood glucose than insulin to increase plasma LEAP2. It remains to be 
seen whether glucose administration-induced increases in plasma LEAP2 contribute to 




Even though we found that plasma LEAP2 is regulated by body mass, acute and 
chronic nutritional status, and blood glucose in a manner opposite to plasma acyl-
ghrelin in humans and mice in the settings discussed above, such reciprocal 
physiological regulation was not observed in obese individuals following VSG or in STZ-
treated mice. In particular, as compared to pre-surgery levels, VSG reduced plasma 
LEAP2 levels (in the post-prandial state but not the fasted state). However, unlike the 
higher plasma acyl-ghrelin observed in normal weight humans (vs. humans with 
obesity) or following diet-induced weight loss, fasted and post-prandial acyl-ghrelin 
concentrations after VSG-induced weight loss were lower than pre-surgery 
concentrations. Furthermore, in mice, STZ administration raised both plasma LEAP2 
and acyl-ghrelin. This might be because of the loss of insulin-mediated suppression of 
ghrelin secretion after STZ (52). Thus, in both those conditions, the mean plasma 
LEAP2:acyl-ghrelin molar ratio remained unchanged, and does not appear to fit within 
the model proposed in Figure 8. Further studies are required to address the potential 
impact of the VSG surgery- and STZ treatment-associated changes to the more usual 
(physiological) pattern of inverse regulation of LEAP2 and acyl-ghrelin and whether this 
dysregulation could impact overall metabolic responses to endogenous or administered 
acyl-ghrelin in those settings.  
 
Altogether, our results suggest a model (Figure 8) in which during negative energy 
balance (acute fasting or longer-term energy restriction), a fall in plasma LEAP2 creates 
a permissive environment for elevated plasma acyl-ghrelin to most effectively act to 
increase food intake and GH secretion, and prevent potentially life-threatening falls in 
Page 28 
 
blood glucose. Our model also predicts that in the settings of obesity, especially in the 
post-prandial state in individuals with severe obesity, and/or raised blood glucose 
stemming from food intake, a coordinated rise in plasma LEAP2 and drop in plasma 
acyl-ghrelin limits acyl-ghrelin’s orexigenic and blood glucose-raising actions. As plasma 
LEAP2 is positively correlated with BMI, we predict that individuals with milder forms of 
obesity, in particular, might benefit from potential weight loss therapies that increase 
plasma LEAP2. So, too, would individuals who have achieved weight loss through 
lifestyle interventions but run the risk of rebound weight gain, as weight loss induces 
falls in plasma LEAP2 and reciprocal rises in plasma acyl-ghrelin. These reciprocal rises 
and falls in plasma LEAP2 and acyl-ghrelin observed upon weight loss from dieting and 
in several other key physiological states become uncoupled following VSG in humans or 
induction of T1DM in mice, although the mechanism of this uncoupling is not yet clear, 
nor is the functional significance. Furthermore, we predict that the plasma LEAP2:acyl-
ghrelin ratio could be a key determinant modulating GHSR signaling in response to 







Male C57BL/6N mice (originally from Charles River Laboratories, Wilmington, MA) bred 
and maintained in our colony were used. Mice were housed under a 12 h dark-light 
cycle with free access to water and standard chow diet [2016 Teklad Global 16% 
protein diet; Envigo, Indianapolis, IN, USA)], unless otherwise indicated.  
 
Diet-induced obesity and weight loss mouse models  
Mice were weaned and individually housed at 3 weeks-of-age. At 4 weeks-of-age, the 
mice were either maintained on standard chow diet or switched to high fat diet (HFD; 
Envigo Teklad TD88137; 42% of kcals are fat-derived) for 16 weeks. After 16 weeks, 
body composition analyses were performed using an EchoMRITM-100 (Echo Medical 
Systems, Houston, TX) and blood samples were collected for plasma LEAP2 and acyl-
ghrelin measurement. The mice were sacrificed 2 weeks after the blood collection to 
harvest organs for quantitative RT-PCR. See Supplemental Methods for the RT-PCR 
protocol used. 
 
To model weight loss after obesity, a separate cohort of individually-housed 4-5 week-
old mice were fed with HFD for 8 weeks to induce weight gain. Thereafter, the HFD-fed 
mice were either kept on HFD for 4 more weeks (obese group) or switched to standard 
chow for 4 weeks to induce weight loss (weight loss group). Mice fed standard chow 
during the entire study duration of 12 weeks served as controls (lean group). Body 
composition analysis and blood collection to measure plasma LEAP2 and acyl-ghrelin 
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occurred at 8 weeks and again at 12 weeks. Body weight was measured weekly 
throughout the study duration.  
  
Type 1 diabetes mellitus mouse model  
Eight-ten week-old mice were administered freshly-prepared streptozotocin (STZ; 150 
mg/kg BW, i.p.) in sodium citrate buffer as vehicle. Control mice were treated with 
vehicle. Blood glucose was measured 6 days later for measurement of blood glucose, 
plasma LEAP2 and acyl-ghrelin.  
 
Human studies 
Three human adult cohorts were used; details regarding participant characteristics are 
available in the Supplemental Methods. Cohort 1 (n=90) was recruited as part of clinical 
research functional magnetic resonance imaging (fMRI) studies at Imperial College 
London, UK (Supplemental Figure 5). The participants included both sexes and 
individuals across diverse body mass index (BMI) categories. During a first visit, 
overnight-fasted venous blood samples were taken at ~10.30 h and 11:00 h (for plasma 
glucose, serum insulin, and triglyceride assays) and at 11:00 h (for LEAP2 and acyl-
ghrelin assays), height and weight were measured to determine BMI, and % body fat 
was determined by bioelectrical impedance analysis (Bodystat 1500, Isle of Man, UK). 
Nearly half the cohort (n=41) had another visit within 1-2 weeks for whole body 
magnetic resonance imaging to determine VAT, SCAT, VAT/SCAT ratio, soleus and 
tibialis muscle intramyocellular lipid (IMCL), and intrahepatocellular (IHCL), as 
described (72, 73). An additional n=15 participants were added to create Cohort 1Ex 
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(n=105 adults), so as to include better representation of participants with obesity; during 
their single study visit, these additional participants had overnight-fasted venous blood 
samples taken for plasma LEAP2 measurement and BMI was determined.   
 
Cohort 2 (n=32) was recruited as part of a previously reported fMRI study (55) at UT 
Southwestern Medical Center and the Veterans Administration North Texas Health Care 
System at Dallas, TX, USA (Supplemental Figure 8). The participants included age-
matched women with either obesity (BMI >35 kg/m2) or normal weight (BMI <25 kg/m2). 
During their visit, overnight-fasted venous blood was collected, a standard meal of 337 
kcal (52% carbohydrates, 30% fat, 18% protein) was consumed, and a post-prandial 
blood sample was collected 1.5 h after the start of meal ingestion. Not published as part 
of the initial report (55), ~2 weeks after the initial study session visit, a subset of the 
cohort 2 women with obesity underwent a VSG procedure (Cohort 2A, n=7). These 
participants returned for a second study session visit 12-18 months post-VSG, during 
which the same protocol detailed above was performed.  
 
Cohort 3 (n=20) was recruited from bariatric clinics at Imperial Weight Centre, St. Mary’s 
Hospital, and Chelsea and Westminster Hospital, London, UK for clinical research 
studies at Imperial College London (Supplemental Figure 9). All individuals had obesity 
(BMI >35 kg/m2). During an initial “post-prandial” visit, they arrived after eating a normal 
breakfast at home, “baseline” venous blood was sampled at ~12:00-13:00h (~5-6 hrs 
after breakfast), they consumed a 600 kcal, 250 mL liquid meal meal (49% 
carbohydrate, 35% fat, 16% protein; Fortisip Compact Vanilla, Nutricia Advanced 
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Medical Nutrition, Trowbridge, Wiltshire, UK), and had repeat blood draws 1 h and 2 h 
after the standardized meal. During a second “fasted” visit ~1 week later, overnight 
fasted venous blood samples were taken at ~13:00 h. BMI was determined and % body 
fat was determined by bioelectrical impedance analysis (BC-418, Tanita Europe VB, 
Amsterdam, Netherlands). Two subsets of Cohort 3 were also studied after RYGB 
surgery. Cohort 3A (n=14) was studied ~3 months post-RYGB (and in n=8 participants, 
again at ~2 yrs post-RYGB) by repeating the “fasted” visit described above. Cohort 3B 
(n=11) was studied ~3 months post-RYGB (~2-3 weeks after having returned to a solid 
diet) by repeating the “post-prandial” visit described above. 
 
Calculation of plasma LEAP2:acyl-ghrelin molar ratio 
Plasma LEAP2 and acyl-ghrelin concentrations in ng/mL were converted to molar 
concentrations by using the formula: molar concentration (mol/L) = mass (g) / [volume 
(L) X molecular weight (g/mol)]. The LEAP2:acyl-ghrelin molar ratio was calculated by 
dividing plasma LEAP2 molar concentration by plasma acyl-ghrelin molar concentration 
for each individual human or mouse. See Supplemental Methods for details on blood 
collection, blood processing, and assays used to measure LEAP2, acyl-ghrelin, blood 
glucose, and other analytes in the human and mouse samples. 
 
Electrophysiology 






Results are presented as dot plots or as box plots displaying median as a line within the 
box, interquartile range (IQR) as the box, 95% confidence intervals (CI) as bars flanking 
the box, outliers as dots (<5%, >95% CI), and mean as a + sign. Within the main text, 
results are presented as mean ± standard error of the mean, except as noted. The 
statistical tests (two-sided) used are indicated in the figure legends, and together with 
the graph preparations were performed using GraphPad Prism v7.0.4 or v8.1.0. Data 
sets not conforming to the assumption of normal distribution (Kolmogorov-Smirnov test 
p<0.05) were analyzed by non-parametric tests. p-values < 0.05 were considered 
statistically significant, and 0.05 ≤ p-values <0.1 were considered evidence of statistical 
trends. Within the figures, p-values are either provided or are denoted as follows: n.s. - 
no significant difference, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Study Approval 
The human studies were approved by the UT Southwestern Medical Center and the 
Veterans Administration North Texas Health Care System at Dallas Institutional Review 
Boards, and UK Research Ethics Committee. The studies were carried out by principles 
outlined in the Declaration of Helsinki and written informed consent was obtained from 
all participants. All animal procedures and use of mice were approved by the 
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